Participant Age Range
30 years to 80 years
“A Randomized, Double-Blind, Placebo-Controlled Proof-of-Concept Study to Assess the Safety and Efficacy of Elezanumab in Acute Ischemic Stroke”
Stroke is one of the top causes of death and major functional disability worldwide. Treatment options for acute ischemic stroke are limited and primarily focus on timely clot removal to restore circulation. A small proportion of patients are eligible for tissue plasminogen activator (tPA) and/or thrombectomy. However, treatment response is incomplete for many patients, and even patients who respond to treatment may have residual neurologic impairment.Elezanumab is an investigational product under development for improvement of neurologic function in patients with acute ischemic stroke. A novel treatment like elezanumab, with a potentially neurorestorative mechanism of action, may improve neurologic function, and represents a significant advance in available treatment options for patients suffering from acute ischemic stroke.